Evidence map›Paper›PMID 29806604›Full record

ArticleThe Indian journal of medical research2018

C-glycosyl flavone from

Ganesh Babu Bevara, A D Naveen Kumar, K Laxmi Koteshwaramma, Anil Badana, Seema Kumari, Rama Rao Malla

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Indian journal of medical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ganesh Babu BevaraDepartment of Biochemistry, Gandhi Institute of Technology & Management (Deemed to be University), Visakhapatnam, India.
A D Naveen KumarDepartment of Biochemistry, Gandhi Institute of Technology & Management (Deemed to be University), Visakhapatnam, India.
K Laxmi KoteshwarammaDepartment of Biochemistry, Gandhi Institute of Technology & Management (Deemed to be University), Visakhapatnam, India.
Anil BadanaDepartment of Biochemistry, Gandhi Institute of Technology & Management (Deemed to be University), Visakhapatnam, India.
Seema KumariDepartment of Biochemistry, Gandhi Institute of Technology & Management (Deemed to be University), Visakhapatnam, India.
Rama Rao MallaDepartment of Biochemistry, Gandhi Institute of Technology & Management (Deemed to be University), Visakhapatnam, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

objectivesSearch for novel compounds beneficial to the treatment of cancer attracts a great deal of attention. We earlier demonstrated the isolation of 5,7-dihydroxy-2-[4'-hydroxy-3'-(methoxymethyl)phenyl]-6-C-β-glucopyranosyl flavone, a novel C-glycosyl flavone from Urginea indica bulb. The present study was undertaken to investigate the effect of this novel compound on human normal epithelial and breast, hepatic and colon cancer cell lines.

methods: The maximum non-toxic concentration (MNTC) and cytotoxicity of C-glycosyl flavone were assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Cell cycle was analyzed by flow cytometry. Docking studies were performed to predict possible targets. Levels of cyclin-dependent kinase 1 (CDK1) and CDK6, Bcl2 and BAX and cytochrome c were quantified by specific ELISA. Mitochondrial membrane potential was determined using JC-1 dye. Apoptosis was quantified by Annexin V ELISA method.

results: Flow cytometry analysis demonstrated G0/G1 arrest. In silico docking studies predicted CDK1 and CDK6 as a possible target of C-glycosyl flavone. In vitro study confirmed CDK6 as the main target in C-glycosyl flavone-treated cancer cell lines. C-glycosyl flavone treatment also induced membrane blebbing, chromatin fragmentation and nucleosome formation. C-glycosyl flavone treatment caused marked loss of mitochondrial membrane potential, decrease in Bcl2/BAX ratio and activation of caspase-3 and release of caspase-9 and cytochrome c. In addition, C-glycosyl flavone inhibited the tumour-induced angiogenesis and reduced the vascular endothelial growth factor levels. Similarly, CDK6 inhibitor significantly inhibited proliferation and angiogenesis and induced apoptosis in tested cell lines. INTERPRETATION &

conclusionsThe results indicate that C-glycosyl flavone may exert induction of apoptosis, cell cycle arrest and inhibition of angiogenesis via CDK6. Thus, targeting CDK6 using C-glycosyl flavone may serve as a novel therapeutic approach for the treatment of breast, hepatic and colon cancers.

Indexed as

ApoptosisBreast NeoplasmsCell CycleCell Line, TumorCell ProliferationColonic NeoplasmsCyclin-Dependent Kinase 6DrimiaFemaleFlavonesGene Expression Regulation, NeoplasticHumansLiver NeoplasmsNeovascularization, PathologicCDK6 protein, humanCyclin-Dependent Kinase 6flavoneFlavonesAngiogenesisapoptosiscell cycleC-glycosyl flavoneUrginea indica

Identifiers

PMID29806604
PMCPMC5991124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.